Press Releases

CD Bioparticles Announces the Launch of New Flow Cytometry Particles

CD Bioparticles has announced a range of new Flow Cytometry Particles.

Revolutionizing Metabolomics: Creative Proteomics Unveils LC-MS/MS Untargeted Metabolomics Service

Innovative SILAC-Based Proteomics Analysis Service Launched by Creative Proteomics

Creative Proteomics Introduces Methionine Cycle Analysis Service for Metabolomics Research

BioIVT Expands its Biospecimen Portfolio in Support of Neuroscience Research

BioIVT will be available to discuss its newly expanded, comprehensive portfolio of neuro-related disease and TruNormal® biospecimens at Neuroscience 2023.

Catawba Research Announces the Promotion of Andrew Silverman, Ph.D., to CEO

Catawba Research, a leading clinical research organization with a goal to become the world’s most trusted CRO, is announcing changes to its executive leadership team.

Phastar Offers Pro Bono Support to Medicines Development for Global Health

Phastar Offers Pro Bono Support to Medicines Development for Global Health Supporting medicine development for disadvantaged communities

MIB Agents Now Accepting Applications for Annual OutSmarting Osteosarcoma Research Grants

Quotient Sciences Announces Major Investment in Sterile Fill/Finish Capacity in Response to Increasing Industry Demand

Maximizing Therapeutic Potential: CD Formulation's Versatile Drug Delivery Systems Advance Pharmacokinetics and Pharmacodynamics

Elligo and Avallano Launching Patient-First, AI-Powered Clinical Trials Ecosystem

Elligo Health Research®, the largest healthcare-enabling research organization, today announced a partnership with Avallano, a data privacy and healthcare technology company, to launch myTrialsConnectSM, a scalable research community powered by artificial intelligence (AI), that was built to serve patients, providers, sites, and the biopharma industry.

Elemental, Ions and Water (Karl Fischer) Standards Make Analytical Testing More Accurate and Easier

Samsung Biologics reports third quarter 2023 financial results

Samsung Biologics (KRX: 207940.KS), the world’s leading contract development and manufacturing organization (CDMO), today announced financial results for the third quarter of fiscal year 2023.

Securing the Integrity of Microneedle Structure Design and Optimization: CD Formulation's Performance Testing Approach

Amerigo Scientific Unveils CRISPR/Cas Enzymes to Expand the CRISPR Toolbox

Profacgen Updated Its Electrophoretic Mobility Shift Assay (EMSA) Service

Creative BioMart Provides a Wide Range of Biomarker Proteins for Research Use

Alfa Chemistry Announces the Launch of Innovative IVD Products for Laboratory Use

CD BioGlyco Releases One-Stop Services for Glycoprotein-Based Vaccine Development

Samsung Biologics and Kurma Partners announce strategic partnership for development and manufacturing of biologics for Kurma’s portfolio companies